LTRN
Lantern Pharma Inc. NASDAQ$2.23
Mkt Cap $25.1M
52w Low $1.11
24.2% of range
52w High $5.74
50d MA $2.30
200d MA $3.43
P/E (TTM)
-1.4x
EV/EBITDA
240.0x
P/B
0.0x
Debt/Equity
0.0x
ROE
-262.0%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
1.75
50d MA
$2.30
200d MA
$3.43
Avg Volume
582.4K
About
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers w…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.46 | -0.36 | +21.7% | 1.24 | +11.3% | +10.5% | +14.5% | +30.6% | +30.6% | +41.9% | — |
| Nov 12, 2025 | AMC | -0.46 | -0.39 | +15.2% | 3.48 | +2.9% | -0.6% | -2.9% | -3.4% | -7.8% | -6.0% | — |
| Aug 13, 2025 | AMC | -0.53 | -0.40 | +24.5% | 4.76 | -5.0% | -4.0% | -4.0% | -6.7% | -6.3% | -6.1% | — |
| May 15, 2025 | AMC | -0.49 | -0.42 | +14.3% | 3.86 | -1.6% | -14.0% | -7.0% | -9.8% | -13.5% | -13.2% | — |
| Mar 27, 2025 | AMC | -0.51 | -0.54 | -5.9% | 3.72 | +0.3% | -4.6% | -4.8% | -11.0% | -8.1% | -12.6% | — |
| Nov 7, 2024 | AMC | -0.56 | -0.42 | +25.0% | 3.42 | -2.0% | +12.3% | +2.6% | +4.7% | +3.2% | +2.0% | — |
| Aug 8, 2024 | AMC | -0.55 | -0.46 | +16.4% | 4.23 | +0.5% | -7.6% | -8.7% | -6.1% | -6.9% | +1.4% | — |
| May 9, 2024 | AMC | -0.43 | -0.51 | -18.6% | 6.81 | -9.7% | -9.5% | -10.6% | -9.1% | -7.0% | -9.8% | — |
| Mar 18, 2024 | AMC | -0.40 | -0.39 | +2.5% | 9.96 | -7.6% | -24.8% | -11.6% | -9.3% | +6.9% | -0.4% | — |
| Nov 8, 2023 | AMC | -0.45 | -0.29 | +35.6% | 2.80 | +5.0% | +33.2% | +17.9% | +34.6% | +45.7% | +43.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10 | EF Hutton | Maintains | Buy → Buy | — | $4.67 | $5.83 | +24.8% | +7.1% | +4.9% | +2.8% | +0.0% | -1.3% |
| Jun 26 | EF Hutton | Maintains | Buy → Buy | — | $5.12 | $5.47 | +6.8% | +2.9% | +1.0% | +2.1% | +0.6% | +10.2% |
| May 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.90 | $4.87 | -0.6% | -4.1% | +2.0% | +5.1% | +4.1% | +5.1% |
| Mar 21 | EF Hutton | Maintains | Buy → Buy | — | $4.65 | $4.87 | +4.7% | -5.4% | -6.9% | -3.7% | -2.9% | -1.5% |
| Feb 15 | EF Hutton | Maintains | Buy → Buy | — | $5.17 | $5.18 | +0.2% | +4.8% | +2.1% | +5.4% | +2.7% | +2.5% |
| Nov 1 | EF Hutton | Maintains | Buy → Buy | — | $4.19 | $4.35 | +3.8% | +5.3% | +1.7% | +5.7% | +2.6% | +6.7% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.55 | $6.99 | +6.7% | +4.4% | -4.6% | -6.9% | +2.3% | +6.7% |
| Nov 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.10 | $10.66 | +5.5% | -1.0% | +3.2% | +2.2% | +2.1% | +0.7% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.49 | $9.90 | +4.3% | +8.0% | +16.3% | +12.6% | +12.5% | +16.1% |
| Jul 28 | Colliers Securities | Maintains | Buy → Buy | — | $12.64 | $12.64 | -0.0% | -3.3% | -2.1% | -3.4% | -2.6% | -1.1% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Litron's Regulation FD disclosure of forward-looking statements from a presentation suggests upcoming product demonstrations or strategic initiatives, but investors should note these are unproven projections requiring careful scrutiny before trading decisions.
Apr 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Lantern Pharma is hosting an earnings call to discuss 2025 full-year results, giving investors a chance to hear management commentary on operational performance and future guidance directly.
Mar 30
Data updated apr 25, 2026 8:01pm
· Source: massive.com